CD4 and non-small cell lung carcinoma: In particular, CD13+CD4+CD25high Tregs exhibited stronger suppressive function than CD4+CD25high Tregs that did not express CD13 and increased in abundance with tumor stage in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab [36].